Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
|Videos|August 17, 2022
Dr. Sebesta on studying social determinants of health
Author(s)Urology Times staff
“I think my goal in doing all this research is to draw awareness to these problems and the disparities,” says Elisabeth M. Sebesta, MD.
Advertisement
In this video, Elisabeth M. Sebesta, MD, shares the take-home message from the recent Neurourology and Urodynamics study, “The burdens of incontinence: Quantifying incontinence product usage and costs in women,” for which she served as a study author. Sebesta is an assistant professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Related to this article
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
Network meta-analysis ranks neoadjuvant options in cisplatin-eligible MIBC
3
Chemoablation expands treatment options for recurrent LG-IR-NMIBC
4
FDA grants breakthrough device designation to urine ID/AST panel
5